Unknown

Dataset Information

0

Efficacy and safety of tenofovir disoproxil fumarate in Asian-Americans with chronic hepatitis B in community settings.


ABSTRACT: BACKGROUND AND AIMS:Chronic hepatitis B (CHB) disproportionately affects the Asian-American population in the USA. Tenofovir disoproxil fumarate (TDF) has demonstrated potent antiviral activity in clinical trials, but data in Asian-Americans from community studies are lacking. METHODS:Adult Asian-American patients with CHB from private medical and community-based practices were prospectively enrolled and treated with open-label TDF 300 mg once daily in a single-arm study for 48 weeks. After Week 48, patients had the option to transition to commercially available CHB therapy. The primary efficacy endpoint was hepatitis B virus (HBV) DNA <400 copies/mL at Week 48. Secondary endpoints were safety and tolerability, serologic and biochemical responses, liver fibrosis by FibroTest, and the development of drug-resistant mutations. RESULTS:Of the 90 patients enrolled, 53 (58%) were hepatitis B e antigen (HBeAg)-positive at baseline. At Week 48, 74 patients (82% overall; 70% HBeAg-positive and 100% HBeAg-negative) had HBV DNA <400 copies/mL. Six (12%) HBeAg-positive patients achieved HBeAg loss/seroconversion. The percentage of patients with alanine aminotransferase in the normal range increased from 26% at baseline to 66% at Week 48. The percentage of patients with F0 (no or minimal) fibrosis by FibroTest increased from 48% to 51%, and those with F4 (severe) fibrosis decreased from 4% to 1%. No resistance to TDF developed. Treatment was well tolerated. Most adverse events were mild in severity and considered unrelated to study drug. CONCLUSIONS:TDF is effective and well tolerated in Asian-American CHB patients in community clinic-based settings, consistent with larger registration trials. Improvement in liver fibrosis was seen in a proportion of patients. No resistance to TDF developed through 48 weeks of treatment. TRIAL REGISTRATION:Clinicaltrial.gov identifier NCT00736190.

SUBMITTER: Pan CQ 

PROVIDER: S-EPMC3942404 | biostudies-literature | 2014

REPOSITORIES: biostudies-literature

altmetric image

Publications

Efficacy and safety of tenofovir disoproxil fumarate in Asian-Americans with chronic hepatitis B in community settings.

Pan Calvin Q CQ   Trinh Huy H   Yao Alan A   Bae Ho H   Lou Lillian L   Chan Sing S  

PloS one 20140304 3


<h4>Background and aims</h4>Chronic hepatitis B (CHB) disproportionately affects the Asian-American population in the USA. Tenofovir disoproxil fumarate (TDF) has demonstrated potent antiviral activity in clinical trials, but data in Asian-Americans from community studies are lacking.<h4>Methods</h4>Adult Asian-American patients with CHB from private medical and community-based practices were prospectively enrolled and treated with open-label TDF 300 mg once daily in a single-arm study for 48 we  ...[more]

Similar Datasets

| S-EPMC9514787 | biostudies-literature
| S-EPMC4427621 | biostudies-literature
| S-EPMC6529393 | biostudies-literature
| S-EPMC4499796 | biostudies-literature
| S-EPMC10443609 | biostudies-literature
| S-EPMC5482834 | biostudies-literature
| S-EPMC6824756 | biostudies-literature
| S-EPMC9143982 | biostudies-literature
| S-EPMC7678628 | biostudies-literature
| S-EPMC5072973 | biostudies-literature